Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

NCT00408954

Last updated date
Study Location
Pfizer Investigational Site
Brno, , 612 00, Czech Republic
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Prostatic Hyperplasia
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male subjects, aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13.

- Clinical diagnosis of BPH

- Qmax 5 to 15 ml/sec with a voided volume of ≥150 ml

- Urodynamically defined bladder outlet obstruction

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- prostate cancer


- Post-void residual urine volume >200 ml


- Documented UTI


- History of relevant urological surgery

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Prostatic HyperplasiaA Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)
NCT01003886
  1. Butuan City, Agusan Del Norte
  2. San Juan, Batangas
  3. Tagbilaran City, Bohol
  4. Quezon City, Diliman
  5. City of San Fernando, La Union
  6. Ermita, Manila
  7. Tondo, Manila
  8. Diliman, Quezon City, Metro Manila
  9. Pasig City, Metro Manila
  10. Angeles City, Pampanga
  11. Angeles City,
  12. Angeles,
  13. Bacolod City,
  14. Baguio City,
  15. Bohol,
  16. Bulacan,
  17. Butuan City,
  18. Cagayan De Oro City,
  19. Cebu City,
  20. Cebu City,
  21. Cebu,
  22. Davao City,
  23. Davao,
  24. Gallares City,
  25. General Santos City,
  26. Iligan City,
  27. Ilocos Norte,
  28. Kalibo Aklan,
  29. Kalibo,
  30. La Union,
  31. Laguna,
  32. Laoag City,
  33. Lingayen, Pangasinan,
  34. Makati City,
  35. Malabon City,
  36. Manadaluyong,
  37. Mandaluyong City,
  38. Mandaluyong,
  39. Mandaue City,
  40. Manila,
  41. Manila,
  42. Marikina City,
  43. Marikina,
  44. Mindanao,
  45. Muntinlupa,
  46. Nueva Ecija,
  47. Nueva Vizcaya,
  48. Ozamis City,
  49. Ozamiz City,
  50. Pampanga,
  51. Pasig City,
  52. Philippines,
  53. Quezon City,
  54. Quezon City,
  55. Quezon City,
  56. Quezon City,
  57. Quezon,
  58. Rizal,
  59. San Jose City,
  60. Surigao City,
  61. Tacloban City,
  62. Tacloban,
  63. Tagbilaran City,
  64. Tagbilaran City,
  65. Tagum City,
  66. Tarlac City,
  67. Tarlac City,
  68. Tarlac,
  69. Tuguegarao City,
  70. Valenzuela City,
  71. Vigan,
  72. Visayas,
  73. West Fairview, Quezon City,
Male
18 Years+
years
MULTIPLE SITES
Prostatic HyperplasiaUrodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
NCT00408954
  1. Brno,
  2. Hradec Kralove,
  3. Olomouc,
  4. Usti nad Labem,
  5. Amsterdam,
  6. Nijmegen,
  7. Bratislava,
  8. Kosice,
  9. Kosice,
  10. Martin,
  11. Trencin,
Male
40 Years+
years
MULTIPLE SITES
Prostatic HyperplasiaStudy the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
NCT00457457
  1. Herston, Queensland
  2. Adelaide, South Australia
  3. Brussels,
  4. Brussels,
  5. Edegem,
  6. Calgary, Alberta
  7. London, Ontario
  8. Pointe-Claire, Quebec
  9. Temuco, IX Region
  10. Santiago,
  11. Medellin, Antioquia
  12. Barranquilla, Atlantico
  13. Bogota, Cundinamarca
  14. Bogota, Cundinamarca
  15. Cali, Valle Del Cauca
  16. Aalborg,
  17. Aarhus N,
  18. Gentofte,
  19. Helsinki,
  20. Kuopio,
  21. Oulu,
  22. Tampere,
  23. Larissa,
  24. Rio,
  25. Thessaloniki,
  26. Foggia,
  27. Siena,
  28. Riga,
  29. Kaunas,
  30. Kaunas,
  31. Vilnius,
  32. Bydgoszcz,
  33. Bydgoszcz,
  34. Gdansk,
  35. Gdynia,
  36. Myslowice,
  37. Wejherowo,
  38. Bratislava,
  39. Malacky,
  40. Nitra,
  41. Prešov,
  42. Skalica,
  43. Madrid,
  44. Malaga,
  45. Valencia,
  46. Bristol,
Male
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
Official Title  ICMJE A Multi Center Randomized Cross Over Double Blind Third Party Open Placebo Controlled Pilot Study to Assess the Urodynamic Effects of Modified Release UK-369,003 in Men With Lower Urinary Tract Symptoms.
Brief Summary This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Prostatic Hyperplasia
Intervention  ICMJE
  • Drug: UK-369,003
    100 mg MR tablet once daily for 2 weeks
  • Drug: UK-369,003
    UK-369,003-100 mg MR formulation for 2 weeks
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: UK-369,003
  • Active Comparator: UK-369,003
    Intervention: Drug: UK-369,003
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 22, 2008)
27
Original Enrollment  ICMJE
 (submitted: December 7, 2006)
20
Actual Study Completion Date  ICMJE June 2008
Actual Primary Completion Date June 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male subjects, aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ?13.
  • Clinical diagnosis of BPH
  • Qmax 5 to 15 ml/sec with a voided volume of ?150 ml
  • Urodynamically defined bladder outlet obstruction

Exclusion Criteria:

  • prostate cancer
  • Post-void residual urine volume >200 ml
  • Documented UTI
  • History of relevant urological surgery
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 40 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Czech Republic,   Netherlands,   Slovakia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00408954
Other Study ID Numbers  ICMJE A3711045
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP